Pear Therapeutics, Inc. (NASDAQ: PEAR) Stock Competitors & Peer Comparison
See PEAR's competitors and their performance on the NASDAQ and across the wider stock market.
Peer Comparison Table: Medical - Healthcare Information Services Industry
Detailed financial metrics including price, market cap, P/E ratio, and more for PEAR and its NASDAQ peers.
| Symbol | Price | Change % | Market Cap | P/E Ratio | EPS | Dividend Yield |
|---|---|---|---|---|---|---|
| PEAR | $0.03 | +0.00% | 4.1M | -0.08 | -$0.36 | N/A |
| GEHC | $71.77 | +2.08% | 32.4B | 15.74 | $4.56 | +0.20% |
| GEHCV | $56.00 | -4.08% | 25.5B | N/A | N/A | N/A |
| BTSG | $62.43 | +3.02% | 12.3B | 50.35 | $1.24 | N/A |
| TEM | $52.05 | +12.86% | 9.1B | -104.10 | -$0.50 | N/A |
| SGFY | $30.49 | +0.07% | 8.9B | 70.91 | $0.43 | N/A |
| HQY | $104.63 | +1.15% | 8.7B | 24.45 | $4.28 | N/A |
| HNGE | $89.33 | +11.55% | 6.9B | 47.81 | $1.87 | N/A |
| TXG | $52.03 | +14.10% | 6.6B | -306.06 | -$0.17 | N/A |
| RCM | $14.31 | N/A | 6B | -102.21 | -$0.14 | N/A |
Stock Comparison
GE HealthCare Technologies Inc. (NASDAQ: GEHC)
PEAR vs GEHC Comparison August 2026
Pear Therapeutics, Inc. (NASDAQ: PEAR) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PEAR stands at 4.1M. In comparison, GEHC has a market cap of 32.4B. Regarding current trading prices, PEAR is priced at $0.03 on the NASDAQ, while GEHC trades at $71.77.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PEAR currently has a P/E ratio of -0.08, whereas GEHC's P/E ratio is 15.74. In terms of profitability, PEAR's ROE is -0.39%, compared to GEHC's ROE of +0.15%. Regarding short-term risk, PEAR is more volatile compared to GEHC. This indicates higher risk in terms of short-term price fluctuations for PEAR.Check GEHC's competition here
GE HealthCare Technologies Inc. (NASDAQ: GEHCV)
PEAR vs GEHCV Comparison August 2026
Pear Therapeutics, Inc. (NASDAQ: PEAR) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PEAR stands at 4.1M. In comparison, GEHCV has a market cap of 25.5B. Regarding current trading prices, PEAR is priced at $0.03 on the NASDAQ, while GEHCV trades at $56.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PEAR currently has a P/E ratio of -0.08, whereas GEHCV's P/E ratio is N/A. In terms of profitability, PEAR's ROE is -0.39%, compared to GEHCV's ROE of +0.19%. Regarding short-term risk, PEAR is more volatile compared to GEHCV. This indicates higher risk in terms of short-term price fluctuations for PEAR.Check GEHCV's competition here
BrightSpring Health Services, Inc. Common Stock (NASDAQ: BTSG)
PEAR vs BTSG Comparison August 2026
Pear Therapeutics, Inc. (NASDAQ: PEAR) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PEAR stands at 4.1M. In comparison, BTSG has a market cap of 12.3B. Regarding current trading prices, PEAR is priced at $0.03 on the NASDAQ, while BTSG trades at $62.43.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PEAR currently has a P/E ratio of -0.08, whereas BTSG's P/E ratio is 50.35. In terms of profitability, PEAR's ROE is -0.39%, compared to BTSG's ROE of +0.15%. Regarding short-term risk, PEAR is more volatile compared to BTSG. This indicates higher risk in terms of short-term price fluctuations for PEAR.Check BTSG's competition here
Tempus AI, Inc. (NASDAQ: TEM)
PEAR vs TEM Comparison August 2026
Pear Therapeutics, Inc. (NASDAQ: PEAR) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PEAR stands at 4.1M. In comparison, TEM has a market cap of 9.1B. Regarding current trading prices, PEAR is priced at $0.03 on the NASDAQ, while TEM trades at $52.05.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PEAR currently has a P/E ratio of -0.08, whereas TEM's P/E ratio is -104.10. In terms of profitability, PEAR's ROE is -0.39%, compared to TEM's ROE of -0.55%. Regarding short-term risk, PEAR is more volatile compared to TEM. This indicates higher risk in terms of short-term price fluctuations for PEAR.Check TEM's competition here
Signify Health, Inc. (NYSE: SGFY)
PEAR vs SGFY Comparison August 2026
Pear Therapeutics, Inc. (NASDAQ: PEAR) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PEAR stands at 4.1M. In comparison, SGFY has a market cap of 8.9B. Regarding current trading prices, PEAR is priced at $0.03 on the NASDAQ, while SGFY trades at $30.49.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PEAR currently has a P/E ratio of -0.08, whereas SGFY's P/E ratio is 70.91. In terms of profitability, PEAR's ROE is -0.39%, compared to SGFY's ROE of -0.15%. Regarding short-term risk, PEAR is more volatile compared to SGFY. This indicates higher risk in terms of short-term price fluctuations for PEAR.Check SGFY's competition here
HealthEquity, Inc. (NASDAQ: HQY)
PEAR vs HQY Comparison August 2026
Pear Therapeutics, Inc. (NASDAQ: PEAR) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PEAR stands at 4.1M. In comparison, HQY has a market cap of 8.7B. Regarding current trading prices, PEAR is priced at $0.03 on the NASDAQ, while HQY trades at $104.63.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PEAR currently has a P/E ratio of -0.08, whereas HQY's P/E ratio is 24.45. In terms of profitability, PEAR's ROE is -0.39%, compared to HQY's ROE of +0.11%. Regarding short-term risk, PEAR is more volatile compared to HQY. This indicates higher risk in terms of short-term price fluctuations for PEAR.Check HQY's competition here
Hinge Health, Inc. (NYSE: HNGE)
PEAR vs HNGE Comparison August 2026
Pear Therapeutics, Inc. (NASDAQ: PEAR) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PEAR stands at 4.1M. In comparison, HNGE has a market cap of 6.9B. Regarding current trading prices, PEAR is priced at $0.03 on the NASDAQ, while HNGE trades at $89.33.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PEAR currently has a P/E ratio of -0.08, whereas HNGE's P/E ratio is 47.81. In terms of profitability, PEAR's ROE is -0.39%, compared to HNGE's ROE of +0.30%. Regarding short-term risk, PEAR is more volatile compared to HNGE. This indicates higher risk in terms of short-term price fluctuations for PEAR.Check HNGE's competition here
10x Genomics, Inc. (NASDAQ: TXG)
PEAR vs TXG Comparison August 2026
Pear Therapeutics, Inc. (NASDAQ: PEAR) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PEAR stands at 4.1M. In comparison, TXG has a market cap of 6.6B. Regarding current trading prices, PEAR is priced at $0.03 on the NASDAQ, while TXG trades at $52.03.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PEAR currently has a P/E ratio of -0.08, whereas TXG's P/E ratio is -306.06. In terms of profitability, PEAR's ROE is -0.39%, compared to TXG's ROE of -0.09%. Regarding short-term risk, PEAR is more volatile compared to TXG. This indicates higher risk in terms of short-term price fluctuations for PEAR.Check TXG's competition here
R1 RCM Inc. (NASDAQ: RCM)
PEAR vs RCM Comparison August 2026
Pear Therapeutics, Inc. (NASDAQ: PEAR) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PEAR stands at 4.1M. In comparison, RCM has a market cap of 6B. Regarding current trading prices, PEAR is priced at $0.03 on the NASDAQ, while RCM trades at $14.31.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PEAR currently has a P/E ratio of -0.08, whereas RCM's P/E ratio is -102.21. In terms of profitability, PEAR's ROE is -0.39%, compared to RCM's ROE of +0.00%. Regarding short-term risk, PEAR is more volatile compared to RCM. This indicates higher risk in terms of short-term price fluctuations for PEAR.Check RCM's competition here
Doximity, Inc. (NYSE: DOCS)
PEAR vs DOCS Comparison August 2026
Pear Therapeutics, Inc. (NASDAQ: PEAR) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PEAR stands at 4.1M. In comparison, DOCS has a market cap of 5.1B. Regarding current trading prices, PEAR is priced at $0.03 on the NASDAQ, while DOCS trades at $27.40.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PEAR currently has a P/E ratio of -0.08, whereas DOCS's P/E ratio is 17.91. In terms of profitability, PEAR's ROE is -0.39%, compared to DOCS's ROE of +0.17%. Regarding short-term risk, PEAR is less volatile compared to DOCS. This indicates lower risk in terms of short-term price fluctuations for PEAR.Check DOCS's competition here
Waystar Holding Corp. (NASDAQ: WAY)
PEAR vs WAY Comparison August 2026
Pear Therapeutics, Inc. (NASDAQ: PEAR) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PEAR stands at 4.1M. In comparison, WAY has a market cap of 4.6B. Regarding current trading prices, PEAR is priced at $0.03 on the NASDAQ, while WAY trades at $24.23.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PEAR currently has a P/E ratio of -0.08, whereas WAY's P/E ratio is 16.05. In terms of profitability, PEAR's ROE is -0.39%, compared to WAY's ROE of +0.04%. Regarding short-term risk, PEAR is more volatile compared to WAY. This indicates higher risk in terms of short-term price fluctuations for PEAR.Check WAY's competition here
1Life Healthcare, Inc. (NASDAQ: ONEM)
PEAR vs ONEM Comparison August 2026
Pear Therapeutics, Inc. (NASDAQ: PEAR) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PEAR stands at 4.1M. In comparison, ONEM has a market cap of 3.4B. Regarding current trading prices, PEAR is priced at $0.03 on the NASDAQ, while ONEM trades at $16.47.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PEAR currently has a P/E ratio of -0.08, whereas ONEM's P/E ratio is -7.77. In terms of profitability, PEAR's ROE is -0.39%, compared to ONEM's ROE of -0.24%. Regarding short-term risk, PEAR is more volatile compared to ONEM. This indicates higher risk in terms of short-term price fluctuations for PEAR.Check ONEM's competition here
Privia Health Group, Inc. (NASDAQ: PRVA)
PEAR vs PRVA Comparison August 2026
Pear Therapeutics, Inc. (NASDAQ: PEAR) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PEAR stands at 4.1M. In comparison, PRVA has a market cap of 2.8B. Regarding current trading prices, PEAR is priced at $0.03 on the NASDAQ, while PRVA trades at $22.45.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PEAR currently has a P/E ratio of -0.08, whereas PRVA's P/E ratio is 106.90. In terms of profitability, PEAR's ROE is -0.39%, compared to PRVA's ROE of +0.00%. Regarding short-term risk, PEAR is more volatile compared to PRVA. This indicates higher risk in terms of short-term price fluctuations for PEAR.Check PRVA's competition here
Heartflow, Inc. Common Stock (NASDAQ: HTFL)
PEAR vs HTFL Comparison August 2026
Pear Therapeutics, Inc. (NASDAQ: PEAR) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PEAR stands at 4.1M. In comparison, HTFL has a market cap of 2.5B. Regarding current trading prices, PEAR is priced at $0.03 on the NASDAQ, while HTFL trades at $28.82.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PEAR currently has a P/E ratio of -0.08, whereas HTFL's P/E ratio is -14.34. In terms of profitability, PEAR's ROE is -0.39%, compared to HTFL's ROE of +8.30%. Regarding short-term risk, PEAR is more volatile compared to HTFL. This indicates higher risk in terms of short-term price fluctuations for PEAR.Check HTFL's competition here
GeneDx Holdings Corp. (NASDAQ: WGS)
PEAR vs WGS Comparison August 2026
Pear Therapeutics, Inc. (NASDAQ: PEAR) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PEAR stands at 4.1M. In comparison, WGS has a market cap of 2.3B. Regarding current trading prices, PEAR is priced at $0.03 on the NASDAQ, while WGS trades at $77.08.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PEAR currently has a P/E ratio of -0.08, whereas WGS's P/E ratio is 214.11. In terms of profitability, PEAR's ROE is -0.39%, compared to WGS's ROE of -0.39%. Regarding short-term risk, PEAR is more volatile compared to WGS. This indicates higher risk in terms of short-term price fluctuations for PEAR.Check WGS's competition here
Progyny, Inc. (NASDAQ: PGNY)
PEAR vs PGNY Comparison August 2026
Pear Therapeutics, Inc. (NASDAQ: PEAR) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PEAR stands at 4.1M. In comparison, PGNY has a market cap of 2.2B. Regarding current trading prices, PEAR is priced at $0.03 on the NASDAQ, while PGNY trades at $28.10.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PEAR currently has a P/E ratio of -0.08, whereas PGNY's P/E ratio is 20.36. In terms of profitability, PEAR's ROE is -0.39%, compared to PGNY's ROE of +0.16%. Regarding short-term risk, PEAR is more volatile compared to PGNY. This indicates higher risk in terms of short-term price fluctuations for PEAR.Check PGNY's competition here
GeneDx Holdings Corp. (NASDAQ: WGSWW)
PEAR vs WGSWW Comparison August 2026
Pear Therapeutics, Inc. (NASDAQ: PEAR) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PEAR stands at 4.1M. In comparison, WGSWW has a market cap of 1.8B. Regarding current trading prices, PEAR is priced at $0.03 on the NASDAQ, while WGSWW trades at $0.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PEAR currently has a P/E ratio of -0.08, whereas WGSWW's P/E ratio is N/A. In terms of profitability, PEAR's ROE is -0.39%, compared to WGSWW's ROE of -0.39%. Regarding short-term risk, PEAR is more volatile compared to WGSWW. This indicates higher risk in terms of short-term price fluctuations for PEAR.Check WGSWW's competition here
NextGen Healthcare, Inc. (NASDAQ: NXGN)
PEAR vs NXGN Comparison August 2026
Pear Therapeutics, Inc. (NASDAQ: PEAR) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PEAR stands at 4.1M. In comparison, NXGN has a market cap of 1.6B. Regarding current trading prices, PEAR is priced at $0.03 on the NASDAQ, while NXGN trades at $23.94.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PEAR currently has a P/E ratio of -0.08, whereas NXGN's P/E ratio is -266.00. In terms of profitability, PEAR's ROE is -0.39%, compared to NXGN's ROE of -0.01%. Regarding short-term risk, PEAR is more volatile compared to NXGN. This indicates higher risk in terms of short-term price fluctuations for PEAR.Check NXGN's competition here
Omada Health (NASDAQ: OMDA)
PEAR vs OMDA Comparison August 2026
Pear Therapeutics, Inc. (NASDAQ: PEAR) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PEAR stands at 4.1M. In comparison, OMDA has a market cap of 1.4B. Regarding current trading prices, PEAR is priced at $0.03 on the NASDAQ, while OMDA trades at $23.67.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PEAR currently has a P/E ratio of -0.08, whereas OMDA's P/E ratio is 338.14. In terms of profitability, PEAR's ROE is -0.39%, compared to OMDA's ROE of +0.02%. Regarding short-term risk, PEAR is more volatile compared to OMDA. This indicates higher risk in terms of short-term price fluctuations for PEAR.Check OMDA's competition here
Agiliti, Inc. (NYSE: AGTI)
PEAR vs AGTI Comparison August 2026
Pear Therapeutics, Inc. (NASDAQ: PEAR) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PEAR stands at 4.1M. In comparison, AGTI has a market cap of 1.4B. Regarding current trading prices, PEAR is priced at $0.03 on the NASDAQ, while AGTI trades at $10.05.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PEAR currently has a P/E ratio of -0.08, whereas AGTI's P/E ratio is -71.79. In terms of profitability, PEAR's ROE is -0.39%, compared to AGTI's ROE of -0.02%. Regarding short-term risk, PEAR is more volatile compared to AGTI. This indicates higher risk in terms of short-term price fluctuations for PEAR.Check AGTI's competition here
Teladoc Health, Inc. (NYSE: TDOC)
PEAR vs TDOC Comparison August 2026
Pear Therapeutics, Inc. (NASDAQ: PEAR) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PEAR stands at 4.1M. In comparison, TDOC has a market cap of 1.3B. Regarding current trading prices, PEAR is priced at $0.03 on the NASDAQ, while TDOC trades at $7.13.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PEAR currently has a P/E ratio of -0.08, whereas TDOC's P/E ratio is -7.92. In terms of profitability, PEAR's ROE is -0.39%, compared to TDOC's ROE of -0.13%. Regarding short-term risk, PEAR is more volatile compared to TDOC. This indicates higher risk in terms of short-term price fluctuations for PEAR.Check TDOC's competition here
Certara, Inc. (NASDAQ: CERT)
PEAR vs CERT Comparison August 2026
Pear Therapeutics, Inc. (NASDAQ: PEAR) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PEAR stands at 4.1M. In comparison, CERT has a market cap of 1.3B. Regarding current trading prices, PEAR is priced at $0.03 on the NASDAQ, while CERT trades at $8.20.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PEAR currently has a P/E ratio of -0.08, whereas CERT's P/E ratio is 20.50. In terms of profitability, PEAR's ROE is -0.39%, compared to CERT's ROE of -0.07%. Regarding short-term risk, PEAR is more volatile compared to CERT. This indicates higher risk in terms of short-term price fluctuations for PEAR.Check CERT's competition here
GoodRx Holdings, Inc. (NASDAQ: GDRX)
PEAR vs GDRX Comparison August 2026
Pear Therapeutics, Inc. (NASDAQ: PEAR) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PEAR stands at 4.1M. In comparison, GDRX has a market cap of 1.3B. Regarding current trading prices, PEAR is priced at $0.03 on the NASDAQ, while GDRX trades at $3.68.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PEAR currently has a P/E ratio of -0.08, whereas GDRX's P/E ratio is 11.50. In terms of profitability, PEAR's ROE is -0.39%, compared to GDRX's ROE of +0.03%. Regarding short-term risk, PEAR is more volatile compared to GDRX. This indicates higher risk in terms of short-term price fluctuations for PEAR.Check GDRX's competition here
CareCloud, Inc. (NASDAQ: CCLDO)
PEAR vs CCLDO Comparison August 2026
Pear Therapeutics, Inc. (NASDAQ: PEAR) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PEAR stands at 4.1M. In comparison, CCLDO has a market cap of 857.3M. Regarding current trading prices, PEAR is priced at $0.03 on the NASDAQ, while CCLDO trades at $27.44.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PEAR currently has a P/E ratio of -0.08, whereas CCLDO's P/E ratio is N/A. In terms of profitability, PEAR's ROE is -0.39%, compared to CCLDO's ROE of +0.17%. Regarding short-term risk, PEAR is more volatile compared to CCLDO. This indicates higher risk in terms of short-term price fluctuations for PEAR.Check CCLDO's competition here
HealthStream, Inc. (NASDAQ: HSTM)
PEAR vs HSTM Comparison August 2026
Pear Therapeutics, Inc. (NASDAQ: PEAR) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PEAR stands at 4.1M. In comparison, HSTM has a market cap of 839.1M. Regarding current trading prices, PEAR is priced at $0.03 on the NASDAQ, while HSTM trades at $28.72.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PEAR currently has a P/E ratio of -0.08, whereas HSTM's P/E ratio is 35.46. In terms of profitability, PEAR's ROE is -0.39%, compared to HSTM's ROE of +0.06%. Regarding short-term risk, PEAR is more volatile compared to HSTM. This indicates higher risk in terms of short-term price fluctuations for PEAR.Check HSTM's competition here
Phreesia, Inc. (NYSE: PHR)
PEAR vs PHR Comparison August 2026
Pear Therapeutics, Inc. (NASDAQ: PEAR) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PEAR stands at 4.1M. In comparison, PHR has a market cap of 773M. Regarding current trading prices, PEAR is priced at $0.03 on the NASDAQ, while PHR trades at $12.51.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PEAR currently has a P/E ratio of -0.08, whereas PHR's P/E ratio is 44.66. In terms of profitability, PEAR's ROE is -0.39%, compared to PHR's ROE of +0.03%. Regarding short-term risk, PEAR is more volatile compared to PHR. This indicates higher risk in terms of short-term price fluctuations for PEAR.Check PHR's competition here
MultiPlan Corporation (NYSE: MPLN-WT)
PEAR vs MPLN-WT Comparison August 2026
Pear Therapeutics, Inc. (NASDAQ: PEAR) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PEAR stands at 4.1M. In comparison, MPLN-WT has a market cap of 625.2M. Regarding current trading prices, PEAR is priced at $0.03 on the NASDAQ, while MPLN-WT trades at $0.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PEAR currently has a P/E ratio of -0.08, whereas MPLN-WT's P/E ratio is N/A. In terms of profitability, PEAR's ROE is -0.39%, compared to MPLN-WT's ROE of +1.40%. Regarding short-term risk, PEAR is less volatile compared to MPLN-WT. This indicates lower risk in terms of short-term price fluctuations for PEAR.Check MPLN-WT's competition here
Accolade, Inc. (NASDAQ: ACCD)
PEAR vs ACCD Comparison August 2026
Pear Therapeutics, Inc. (NASDAQ: PEAR) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PEAR stands at 4.1M. In comparison, ACCD has a market cap of 575.6M. Regarding current trading prices, PEAR is priced at $0.03 on the NASDAQ, while ACCD trades at $7.02.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PEAR currently has a P/E ratio of -0.08, whereas ACCD's P/E ratio is -3.08. In terms of profitability, PEAR's ROE is -0.39%, compared to ACCD's ROE of -0.22%. Regarding short-term risk, PEAR is more volatile compared to ACCD. This indicates higher risk in terms of short-term price fluctuations for PEAR.Check ACCD's competition here
Claritev Corporation (NYSE: CTEV)
PEAR vs CTEV Comparison August 2026
Pear Therapeutics, Inc. (NASDAQ: PEAR) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PEAR stands at 4.1M. In comparison, CTEV has a market cap of 546.7M. Regarding current trading prices, PEAR is priced at $0.03 on the NASDAQ, while CTEV trades at $32.59.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PEAR currently has a P/E ratio of -0.08, whereas CTEV's P/E ratio is -2.46. In terms of profitability, PEAR's ROE is -0.39%, compared to CTEV's ROE of +1.40%. Regarding short-term risk, PEAR is more volatile compared to CTEV. This indicates higher risk in terms of short-term price fluctuations for PEAR.Check CTEV's competition here
SOPHiA GENETICS S.A. (NASDAQ: SOPH)
PEAR vs SOPH Comparison August 2026
Pear Therapeutics, Inc. (NASDAQ: PEAR) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PEAR stands at 4.1M. In comparison, SOPH has a market cap of 537.5M. Regarding current trading prices, PEAR is priced at $0.03 on the NASDAQ, while SOPH trades at $7.71.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PEAR currently has a P/E ratio of -0.08, whereas SOPH's P/E ratio is -6.95. In terms of profitability, PEAR's ROE is -0.39%, compared to SOPH's ROE of -1.41%. Regarding short-term risk, PEAR is more volatile compared to SOPH. This indicates higher risk in terms of short-term price fluctuations for PEAR.Check SOPH's competition here
Sharecare, Inc. (NASDAQ: SHCR)
PEAR vs SHCR Comparison August 2026
Pear Therapeutics, Inc. (NASDAQ: PEAR) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PEAR stands at 4.1M. In comparison, SHCR has a market cap of 531.8M. Regarding current trading prices, PEAR is priced at $0.03 on the NASDAQ, while SHCR trades at $1.43.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PEAR currently has a P/E ratio of -0.08, whereas SHCR's P/E ratio is -3.76. In terms of profitability, PEAR's ROE is -0.39%, compared to SHCR's ROE of -0.25%. Regarding short-term risk, PEAR is more volatile compared to SHCR. This indicates higher risk in terms of short-term price fluctuations for PEAR.Check SHCR's competition here
NRC Health (NASDAQ: NRC)
PEAR vs NRC Comparison August 2026
Pear Therapeutics, Inc. (NASDAQ: PEAR) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PEAR stands at 4.1M. In comparison, NRC has a market cap of 458.4M. Regarding current trading prices, PEAR is priced at $0.03 on the NASDAQ, while NRC trades at $20.34.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PEAR currently has a P/E ratio of -0.08, whereas NRC's P/E ratio is 24.80. In terms of profitability, PEAR's ROE is -0.39%, compared to NRC's ROE of +0.48%. Regarding short-term risk, PEAR is more volatile compared to NRC. This indicates higher risk in terms of short-term price fluctuations for PEAR.Check NRC's competition here
Evolent Health, Inc. (NYSE: EVH)
PEAR vs EVH Comparison August 2026
Pear Therapeutics, Inc. (NASDAQ: PEAR) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PEAR stands at 4.1M. In comparison, EVH has a market cap of 446M. Regarding current trading prices, PEAR is priced at $0.03 on the NASDAQ, while EVH trades at $3.95.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PEAR currently has a P/E ratio of -0.08, whereas EVH's P/E ratio is 30.50. In terms of profitability, PEAR's ROE is -0.39%, compared to EVH's ROE of -0.99%. Regarding short-term risk, PEAR is more volatile compared to EVH. This indicates higher risk in terms of short-term price fluctuations for PEAR.Check EVH's competition here
SomaLogic, Inc. (NASDAQ: SLGC)
PEAR vs SLGC Comparison August 2026
Pear Therapeutics, Inc. (NASDAQ: PEAR) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PEAR stands at 4.1M. In comparison, SLGC has a market cap of 396.2M. Regarding current trading prices, PEAR is priced at $0.03 on the NASDAQ, while SLGC trades at $2.10.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PEAR currently has a P/E ratio of -0.08, whereas SLGC's P/E ratio is -3.04. In terms of profitability, PEAR's ROE is -0.39%, compared to SLGC's ROE of -0.19%. Regarding short-term risk, PEAR is more volatile compared to SLGC. This indicates higher risk in terms of short-term price fluctuations for PEAR.Check SLGC's competition here
SomaLogic, Inc. (NASDAQ: SLGCW)
PEAR vs SLGCW Comparison August 2026
Pear Therapeutics, Inc. (NASDAQ: PEAR) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PEAR stands at 4.1M. In comparison, SLGCW has a market cap of 396.2M. Regarding current trading prices, PEAR is priced at $0.03 on the NASDAQ, while SLGCW trades at $0.09.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PEAR currently has a P/E ratio of -0.08, whereas SLGCW's P/E ratio is -0.16. In terms of profitability, PEAR's ROE is -0.39%, compared to SLGCW's ROE of -0.19%. Regarding short-term risk, PEAR is more volatile compared to SLGCW. This indicates higher risk in terms of short-term price fluctuations for PEAR.Check SLGCW's competition here
TruBridge, Inc. (NASDAQ: TBRG)
PEAR vs TBRG Comparison August 2026
Pear Therapeutics, Inc. (NASDAQ: PEAR) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PEAR stands at 4.1M. In comparison, TBRG has a market cap of 393.6M. Regarding current trading prices, PEAR is priced at $0.03 on the NASDAQ, while TBRG trades at $26.24.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PEAR currently has a P/E ratio of -0.08, whereas TBRG's P/E ratio is 9.37. In terms of profitability, PEAR's ROE is -0.39%, compared to TBRG's ROE of +0.02%. Regarding short-term risk, PEAR is more volatile compared to TBRG. This indicates higher risk in terms of short-term price fluctuations for PEAR.Check TBRG's competition here
MultiPlan Corporation (NYSE: MPLN)
PEAR vs MPLN Comparison August 2026
Pear Therapeutics, Inc. (NASDAQ: PEAR) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PEAR stands at 4.1M. In comparison, MPLN has a market cap of 375M. Regarding current trading prices, PEAR is priced at $0.03 on the NASDAQ, while MPLN trades at $23.15.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PEAR currently has a P/E ratio of -0.08, whereas MPLN's P/E ratio is -0.23. In terms of profitability, PEAR's ROE is -0.39%, compared to MPLN's ROE of +1.40%. Regarding short-term risk, PEAR is more volatile compared to MPLN. This indicates higher risk in terms of short-term price fluctuations for PEAR.Check MPLN's competition here
So-Young International Inc. (NASDAQ: SY)
PEAR vs SY Comparison August 2026
Pear Therapeutics, Inc. (NASDAQ: PEAR) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PEAR stands at 4.1M. In comparison, SY has a market cap of 286M. Regarding current trading prices, PEAR is priced at $0.03 on the NASDAQ, while SY trades at $2.18.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PEAR currently has a P/E ratio of -0.08, whereas SY's P/E ratio is -6.61. In terms of profitability, PEAR's ROE is -0.39%, compared to SY's ROE of -0.16%. Regarding short-term risk, PEAR is more volatile compared to SY. This indicates higher risk in terms of short-term price fluctuations for PEAR.Check SY's competition here
Tabula Rasa HealthCare, Inc. (NASDAQ: TRHC)
PEAR vs TRHC Comparison August 2026
Pear Therapeutics, Inc. (NASDAQ: PEAR) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PEAR stands at 4.1M. In comparison, TRHC has a market cap of 284M. Regarding current trading prices, PEAR is priced at $0.03 on the NASDAQ, while TRHC trades at $10.50.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PEAR currently has a P/E ratio of -0.08, whereas TRHC's P/E ratio is -4.27. In terms of profitability, PEAR's ROE is -0.39%, compared to TRHC's ROE of +121.31%. Regarding short-term risk, PEAR is more volatile compared to TRHC. This indicates higher risk in terms of short-term price fluctuations for PEAR.Check TRHC's competition here
Sema4 Holdings Corp. (NASDAQ: SMFR)
PEAR vs SMFR Comparison August 2026
Pear Therapeutics, Inc. (NASDAQ: PEAR) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PEAR stands at 4.1M. In comparison, SMFR has a market cap of 246.4M. Regarding current trading prices, PEAR is priced at $0.03 on the NASDAQ, while SMFR trades at $0.31.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PEAR currently has a P/E ratio of -0.08, whereas SMFR's P/E ratio is N/A. In terms of profitability, PEAR's ROE is -0.39%, compared to SMFR's ROE of -0.39%. Regarding short-term risk, PEAR is more volatile compared to SMFR. This indicates higher risk in terms of short-term price fluctuations for PEAR.Check SMFR's competition here
Spok Holdings, Inc. (NASDAQ: SPOK)
PEAR vs SPOK Comparison August 2026
Pear Therapeutics, Inc. (NASDAQ: PEAR) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PEAR stands at 4.1M. In comparison, SPOK has a market cap of 240.6M. Regarding current trading prices, PEAR is priced at $0.03 on the NASDAQ, while SPOK trades at $11.52.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PEAR currently has a P/E ratio of -0.08, whereas SPOK's P/E ratio is 19.20. In terms of profitability, PEAR's ROE is -0.39%, compared to SPOK's ROE of +0.09%. Regarding short-term risk, PEAR is more volatile compared to SPOK. This indicates higher risk in terms of short-term price fluctuations for PEAR.Check SPOK's competition here
American Well Corporation (NYSE: AMWL)
PEAR vs AMWL Comparison August 2026
Pear Therapeutics, Inc. (NASDAQ: PEAR) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PEAR stands at 4.1M. In comparison, AMWL has a market cap of 228.6M. Regarding current trading prices, PEAR is priced at $0.03 on the NASDAQ, while AMWL trades at $13.52.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PEAR currently has a P/E ratio of -0.08, whereas AMWL's P/E ratio is -3.04. In terms of profitability, PEAR's ROE is -0.39%, compared to AMWL's ROE of -0.33%. Regarding short-term risk, PEAR is more volatile compared to AMWL. This indicates higher risk in terms of short-term price fluctuations for PEAR.Check AMWL's competition here
Computer Programs and Systems, Inc. (NASDAQ: CPSI)
PEAR vs CPSI Comparison August 2026
Pear Therapeutics, Inc. (NASDAQ: PEAR) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PEAR stands at 4.1M. In comparison, CPSI has a market cap of 133.7M. Regarding current trading prices, PEAR is priced at $0.03 on the NASDAQ, while CPSI trades at $9.19.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PEAR currently has a P/E ratio of -0.08, whereas CPSI's P/E ratio is -183.80. In terms of profitability, PEAR's ROE is -0.39%, compared to CPSI's ROE of +0.02%. Regarding short-term risk, PEAR is more volatile compared to CPSI. This indicates higher risk in terms of short-term price fluctuations for PEAR.Check CPSI's competition here
OptimizeRx Corp. (NASDAQ: OPRX)
PEAR vs OPRX Comparison August 2026
Pear Therapeutics, Inc. (NASDAQ: PEAR) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PEAR stands at 4.1M. In comparison, OPRX has a market cap of 132.9M. Regarding current trading prices, PEAR is priced at $0.03 on the NASDAQ, while OPRX trades at $7.08.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PEAR currently has a P/E ratio of -0.08, whereas OPRX's P/E ratio is 6.50. In terms of profitability, PEAR's ROE is -0.39%, compared to OPRX's ROE of +0.05%. Regarding short-term risk, PEAR is more volatile compared to OPRX. This indicates higher risk in terms of short-term price fluctuations for PEAR.Check OPRX's competition here
Health Catalyst, Inc. (NASDAQ: HCAT)
PEAR vs HCAT Comparison August 2026
Pear Therapeutics, Inc. (NASDAQ: PEAR) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PEAR stands at 4.1M. In comparison, HCAT has a market cap of 127.8M. Regarding current trading prices, PEAR is priced at $0.03 on the NASDAQ, while HCAT trades at $1.73.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PEAR currently has a P/E ratio of -0.08, whereas HCAT's P/E ratio is 8.65. In terms of profitability, PEAR's ROE is -0.39%, compared to HCAT's ROE of -1.30%. Regarding short-term risk, PEAR is more volatile compared to HCAT. This indicates higher risk in terms of short-term price fluctuations for PEAR.Check HCAT's competition here
Augmedix, Inc. (NASDAQ: AUGX)
PEAR vs AUGX Comparison August 2026
Pear Therapeutics, Inc. (NASDAQ: PEAR) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PEAR stands at 4.1M. In comparison, AUGX has a market cap of 115.9M. Regarding current trading prices, PEAR is priced at $0.03 on the NASDAQ, while AUGX trades at $2.35.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PEAR currently has a P/E ratio of -0.08, whereas AUGX's P/E ratio is -4.99. In terms of profitability, PEAR's ROE is -0.39%, compared to AUGX's ROE of -1.55%. Regarding short-term risk, PEAR is more volatile compared to AUGX. This indicates higher risk in terms of short-term price fluctuations for PEAR.Check AUGX's competition here
CareCloud, Inc. (NASDAQ: CCLD)
PEAR vs CCLD Comparison August 2026
Pear Therapeutics, Inc. (NASDAQ: PEAR) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PEAR stands at 4.1M. In comparison, CCLD has a market cap of 111.8M. Regarding current trading prices, PEAR is priced at $0.03 on the NASDAQ, while CCLD trades at $2.63.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PEAR currently has a P/E ratio of -0.08, whereas CCLD's P/E ratio is 10.12. In terms of profitability, PEAR's ROE is -0.39%, compared to CCLD's ROE of +0.17%. Regarding short-term risk, PEAR is more volatile compared to CCLD. This indicates higher risk in terms of short-term price fluctuations for PEAR.Check CCLD's competition here
Definitive Healthcare Corp. (NASDAQ: DH)
PEAR vs DH Comparison August 2026
Pear Therapeutics, Inc. (NASDAQ: PEAR) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PEAR stands at 4.1M. In comparison, DH has a market cap of 75.3M. Regarding current trading prices, PEAR is priced at $0.03 on the NASDAQ, while DH trades at $0.71.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PEAR currently has a P/E ratio of -0.08, whereas DH's P/E ratio is 2.74. In terms of profitability, PEAR's ROE is -0.39%, compared to DH's ROE of -0.67%. Regarding short-term risk, PEAR is more volatile compared to DH. This indicates higher risk in terms of short-term price fluctuations for PEAR.Check DH's competition here
SCWorx Corp. (NASDAQ: WORX)
PEAR vs WORX Comparison August 2026
Pear Therapeutics, Inc. (NASDAQ: PEAR) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PEAR stands at 4.1M. In comparison, WORX has a market cap of 72.8M. Regarding current trading prices, PEAR is priced at $0.03 on the NASDAQ, while WORX trades at $4.55.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PEAR currently has a P/E ratio of -0.08, whereas WORX's P/E ratio is -5.29. In terms of profitability, PEAR's ROE is -0.39%, compared to WORX's ROE of -0.65%. Regarding short-term risk, PEAR is less volatile compared to WORX. This indicates lower risk in terms of short-term price fluctuations for PEAR.Check WORX's competition here
Forian Inc. (NASDAQ: FORA)
PEAR vs FORA Comparison August 2026
Pear Therapeutics, Inc. (NASDAQ: PEAR) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PEAR stands at 4.1M. In comparison, FORA has a market cap of 67.8M. Regarding current trading prices, PEAR is priced at $0.03 on the NASDAQ, while FORA trades at $2.17.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PEAR currently has a P/E ratio of -0.08, whereas FORA's P/E ratio is -24.11. In terms of profitability, PEAR's ROE is -0.39%, compared to FORA's ROE of -0.17%. Regarding short-term risk, PEAR is more volatile compared to FORA. This indicates higher risk in terms of short-term price fluctuations for PEAR.Check FORA's competition here
CareCloud, Inc. (NASDAQ: CCLDP)
PEAR vs CCLDP Comparison August 2026
Pear Therapeutics, Inc. (NASDAQ: PEAR) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PEAR stands at 4.1M. In comparison, CCLDP has a market cap of 59.9M. Regarding current trading prices, PEAR is priced at $0.03 on the NASDAQ, while CCLDP trades at $19.43.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PEAR currently has a P/E ratio of -0.08, whereas CCLDP's P/E ratio is N/A. In terms of profitability, PEAR's ROE is -0.39%, compared to CCLDP's ROE of +0.17%. Regarding short-term risk, PEAR is more volatile compared to CCLDP. This indicates higher risk in terms of short-term price fluctuations for PEAR.Check CCLDP's competition here
OneMedNet Corporation (NASDAQ: ONMDW)
PEAR vs ONMDW Comparison August 2026
Pear Therapeutics, Inc. (NASDAQ: PEAR) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PEAR stands at 4.1M. In comparison, ONMDW has a market cap of 37M. Regarding current trading prices, PEAR is priced at $0.03 on the NASDAQ, while ONMDW trades at $0.04.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PEAR currently has a P/E ratio of -0.08, whereas ONMDW's P/E ratio is N/A. In terms of profitability, PEAR's ROE is -0.39%, compared to ONMDW's ROE of +0.90%. Regarding short-term risk, PEAR is more volatile compared to ONMDW. This indicates higher risk in terms of short-term price fluctuations for PEAR.Check ONMDW's competition here
OneMedNet Corporation (NASDAQ: ONMD)
PEAR vs ONMD Comparison August 2026
Pear Therapeutics, Inc. (NASDAQ: PEAR) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PEAR stands at 4.1M. In comparison, ONMD has a market cap of 35.6M. Regarding current trading prices, PEAR is priced at $0.03 on the NASDAQ, while ONMD trades at $0.62.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PEAR currently has a P/E ratio of -0.08, whereas ONMD's P/E ratio is -4.16. In terms of profitability, PEAR's ROE is -0.39%, compared to ONMD's ROE of +0.90%. Regarding short-term risk, PEAR is more volatile compared to ONMD. This indicates higher risk in terms of short-term price fluctuations for PEAR.Check ONMD's competition here
Science 37 Holdings, Inc. (NASDAQ: SNCE)
PEAR vs SNCE Comparison August 2026
Pear Therapeutics, Inc. (NASDAQ: PEAR) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PEAR stands at 4.1M. In comparison, SNCE has a market cap of 34.7M. Regarding current trading prices, PEAR is priced at $0.03 on the NASDAQ, while SNCE trades at $5.75.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PEAR currently has a P/E ratio of -0.08, whereas SNCE's P/E ratio is -0.27. In terms of profitability, PEAR's ROE is -0.39%, compared to SNCE's ROE of -0.47%. Regarding short-term risk, PEAR is more volatile compared to SNCE. This indicates higher risk in terms of short-term price fluctuations for PEAR.Check SNCE's competition here
Akili, Inc. (NASDAQ: AKLI)
PEAR vs AKLI Comparison August 2026
Pear Therapeutics, Inc. (NASDAQ: PEAR) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PEAR stands at 4.1M. In comparison, AKLI has a market cap of 34.1M. Regarding current trading prices, PEAR is priced at $0.03 on the NASDAQ, while AKLI trades at $0.43.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PEAR currently has a P/E ratio of -0.08, whereas AKLI's P/E ratio is -0.71. In terms of profitability, PEAR's ROE is -0.39%, compared to AKLI's ROE of -0.70%. Regarding short-term risk, PEAR is more volatile compared to AKLI. This indicates higher risk in terms of short-term price fluctuations for PEAR.Check AKLI's competition here
SHL Telemedicine Ltd. (NASDAQ: SHLT)
PEAR vs SHLT Comparison August 2026
Pear Therapeutics, Inc. (NASDAQ: PEAR) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PEAR stands at 4.1M. In comparison, SHLT has a market cap of 33.6M. Regarding current trading prices, PEAR is priced at $0.03 on the NASDAQ, while SHLT trades at $2.05.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PEAR currently has a P/E ratio of -0.08, whereas SHLT's P/E ratio is -3.87. In terms of profitability, PEAR's ROE is -0.39%, compared to SHLT's ROE of -0.50%. Regarding short-term risk, PEAR is more volatile compared to SHLT. This indicates higher risk in terms of short-term price fluctuations for PEAR.Check SHLT's competition here
Sharecare, Inc. (NASDAQ: SHCRW)
PEAR vs SHCRW Comparison August 2026
Pear Therapeutics, Inc. (NASDAQ: PEAR) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PEAR stands at 4.1M. In comparison, SHCRW has a market cap of 32.5M. Regarding current trading prices, PEAR is priced at $0.03 on the NASDAQ, while SHCRW trades at $0.09.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PEAR currently has a P/E ratio of -0.08, whereas SHCRW's P/E ratio is -0.00. In terms of profitability, PEAR's ROE is -0.39%, compared to SHCRW's ROE of -0.25%. Regarding short-term risk, PEAR is more volatile compared to SHCRW. This indicates higher risk in terms of short-term price fluctuations for PEAR.Check SHCRW's competition here
Streamline Health Solutions, Inc. (NASDAQ: STRM)
PEAR vs STRM Comparison August 2026
Pear Therapeutics, Inc. (NASDAQ: PEAR) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PEAR stands at 4.1M. In comparison, STRM has a market cap of 23.2M. Regarding current trading prices, PEAR is priced at $0.03 on the NASDAQ, while STRM trades at $5.33.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PEAR currently has a P/E ratio of -0.08, whereas STRM's P/E ratio is -2.40. In terms of profitability, PEAR's ROE is -0.39%, compared to STRM's ROE of -0.65%. Regarding short-term risk, PEAR is more volatile compared to STRM. This indicates higher risk in terms of short-term price fluctuations for PEAR.Check STRM's competition here
Renalytix Plc (NASDAQ: RNLX)
PEAR vs RNLX Comparison August 2026
Pear Therapeutics, Inc. (NASDAQ: PEAR) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PEAR stands at 4.1M. In comparison, RNLX has a market cap of 22.5M. Regarding current trading prices, PEAR is priced at $0.03 on the NASDAQ, while RNLX trades at $0.21.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PEAR currently has a P/E ratio of -0.08, whereas RNLX's P/E ratio is -0.33. In terms of profitability, PEAR's ROE is -0.39%, compared to RNLX's ROE of -6.31%. Regarding short-term risk, PEAR is more volatile compared to RNLX. This indicates higher risk in terms of short-term price fluctuations for PEAR.Check RNLX's competition here
MSP Recovery, Inc. (NASDAQ: LIFW)
PEAR vs LIFW Comparison August 2026
Pear Therapeutics, Inc. (NASDAQ: PEAR) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PEAR stands at 4.1M. In comparison, LIFW has a market cap of 22.4M. Regarding current trading prices, PEAR is priced at $0.03 on the NASDAQ, while LIFW trades at $3.24.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PEAR currently has a P/E ratio of -0.08, whereas LIFW's P/E ratio is -0.02. In terms of profitability, PEAR's ROE is -0.39%, compared to LIFW's ROE of +1.56%. Regarding short-term risk, PEAR is more volatile compared to LIFW. This indicates higher risk in terms of short-term price fluctuations for PEAR.Check LIFW's competition here
Babylon Holdings Limited (NYSE: BBLN)
PEAR vs BBLN Comparison August 2026
Pear Therapeutics, Inc. (NASDAQ: PEAR) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PEAR stands at 4.1M. In comparison, BBLN has a market cap of 14.1M. Regarding current trading prices, PEAR is priced at $0.03 on the NASDAQ, while BBLN trades at $0.55.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PEAR currently has a P/E ratio of -0.08, whereas BBLN's P/E ratio is -0.04. In terms of profitability, PEAR's ROE is -0.39%, compared to BBLN's ROE of +4.89%. Regarding short-term risk, PEAR is more volatile compared to BBLN. This indicates higher risk in terms of short-term price fluctuations for PEAR.Check BBLN's competition here
HeartBeam, Inc. (NASDAQ: BEATW)
PEAR vs BEATW Comparison August 2026
Pear Therapeutics, Inc. (NASDAQ: PEAR) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PEAR stands at 4.1M. In comparison, BEATW has a market cap of 11.7M. Regarding current trading prices, PEAR is priced at $0.03 on the NASDAQ, while BEATW trades at $0.02.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PEAR currently has a P/E ratio of -0.08, whereas BEATW's P/E ratio is -0.03. In terms of profitability, PEAR's ROE is -0.39%, compared to BEATW's ROE of -10.34%. Regarding short-term risk, PEAR is more volatile compared to BEATW. This indicates higher risk in terms of short-term price fluctuations for PEAR.Check BEATW's competition here
ETAO International Co., Ltd. (NASDAQ: ETAO)
PEAR vs ETAO Comparison August 2026
Pear Therapeutics, Inc. (NASDAQ: PEAR) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PEAR stands at 4.1M. In comparison, ETAO has a market cap of 9.8M. Regarding current trading prices, PEAR is priced at $0.03 on the NASDAQ, while ETAO trades at $1.91.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PEAR currently has a P/E ratio of -0.08, whereas ETAO's P/E ratio is -0.01. In terms of profitability, PEAR's ROE is -0.39%, compared to ETAO's ROE of -13.69%. Regarding short-term risk, PEAR is less volatile compared to ETAO. This indicates lower risk in terms of short-term price fluctuations for PEAR.Check ETAO's competition here
Mangoceuticals, Inc. (NASDAQ: MGRX)
PEAR vs MGRX Comparison August 2026
Pear Therapeutics, Inc. (NASDAQ: PEAR) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PEAR stands at 4.1M. In comparison, MGRX has a market cap of 8.3M. Regarding current trading prices, PEAR is priced at $0.03 on the NASDAQ, while MGRX trades at $0.49.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PEAR currently has a P/E ratio of -0.08, whereas MGRX's P/E ratio is -0.36. In terms of profitability, PEAR's ROE is -0.39%, compared to MGRX's ROE of -1.21%. Regarding short-term risk, PEAR is more volatile compared to MGRX. This indicates higher risk in terms of short-term price fluctuations for PEAR.Check MGRX's competition here
Bullfrog AI Holdings, Inc. Common Stock (NASDAQ: BFRG)
PEAR vs BFRG Comparison August 2026
Pear Therapeutics, Inc. (NASDAQ: PEAR) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PEAR stands at 4.1M. In comparison, BFRG has a market cap of 6.9M. Regarding current trading prices, PEAR is priced at $0.03 on the NASDAQ, while BFRG trades at $0.59.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PEAR currently has a P/E ratio of -0.08, whereas BFRG's P/E ratio is -1.09. In terms of profitability, PEAR's ROE is -0.39%, compared to BFRG's ROE of -2.18%. Regarding short-term risk, PEAR is more volatile compared to BFRG. This indicates higher risk in terms of short-term price fluctuations for PEAR.Check BFRG's competition here
Scienture Holdings, Inc. (NASDAQ: SCNX)
PEAR vs SCNX Comparison August 2026
Pear Therapeutics, Inc. (NASDAQ: PEAR) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PEAR stands at 4.1M. In comparison, SCNX has a market cap of 5.9M. Regarding current trading prices, PEAR is priced at $0.03 on the NASDAQ, while SCNX trades at $0.38.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PEAR currently has a P/E ratio of -0.08, whereas SCNX's P/E ratio is -0.15. In terms of profitability, PEAR's ROE is -0.39%, compared to SCNX's ROE of -0.00%. Regarding short-term risk, PEAR is more volatile compared to SCNX. This indicates higher risk in terms of short-term price fluctuations for PEAR.Check SCNX's competition here
UpHealth, Inc. (NYSE: UPH-WT)
PEAR vs UPH-WT Comparison August 2026
Pear Therapeutics, Inc. (NASDAQ: PEAR) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PEAR stands at 4.1M. In comparison, UPH-WT has a market cap of 5.3M. Regarding current trading prices, PEAR is priced at $0.03 on the NASDAQ, while UPH-WT trades at $0.01.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PEAR currently has a P/E ratio of -0.08, whereas UPH-WT's P/E ratio is N/A. In terms of profitability, PEAR's ROE is -0.39%, compared to UPH-WT's ROE of -1.05%. Regarding short-term risk, PEAR is less volatile compared to UPH-WT. This indicates lower risk in terms of short-term price fluctuations for PEAR.Check UPH-WT's competition here
UpHealth, Inc. (NYSE: UPH)
PEAR vs UPH Comparison August 2026
Pear Therapeutics, Inc. (NASDAQ: PEAR) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PEAR stands at 4.1M. In comparison, UPH has a market cap of 5.3M. Regarding current trading prices, PEAR is priced at $0.03 on the NASDAQ, while UPH trades at $0.30.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PEAR currently has a P/E ratio of -0.08, whereas UPH's P/E ratio is -0.07. In terms of profitability, PEAR's ROE is -0.39%, compared to UPH's ROE of -1.05%. Regarding short-term risk, PEAR is more volatile compared to UPH. This indicates higher risk in terms of short-term price fluctuations for PEAR.Check UPH's competition here
Pear Therapeutics, Inc. (NASDAQ: PEARW)
PEAR vs PEARW Comparison August 2026
Pear Therapeutics, Inc. (NASDAQ: PEAR) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PEAR stands at 4.1M. In comparison, PEARW has a market cap of 4.1M. Regarding current trading prices, PEAR is priced at $0.03 on the NASDAQ, while PEARW trades at $0.01.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PEAR currently has a P/E ratio of -0.08, whereas PEARW's P/E ratio is -0.00. In terms of profitability, PEAR's ROE is -0.39%, compared to PEARW's ROE of -0.39%. Regarding short-term risk, PEAR is more volatile compared to PEARW. This indicates higher risk in terms of short-term price fluctuations for PEAR.Check PEARW's competition here
Ontrak, Inc. (NASDAQ: OTRK)
PEAR vs OTRK Comparison August 2026
Pear Therapeutics, Inc. (NASDAQ: PEAR) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PEAR stands at 4.1M. In comparison, OTRK has a market cap of 2.3M. Regarding current trading prices, PEAR is priced at $0.03 on the NASDAQ, while OTRK trades at $0.33.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PEAR currently has a P/E ratio of -0.08, whereas OTRK's P/E ratio is -0.02. In terms of profitability, PEAR's ROE is -0.39%, compared to OTRK's ROE of -2.11%. Regarding short-term risk, PEAR is more volatile compared to OTRK. This indicates higher risk in terms of short-term price fluctuations for PEAR.Check OTRK's competition here
CareMax, Inc. (NASDAQ: CMAX)
PEAR vs CMAX Comparison August 2026
Pear Therapeutics, Inc. (NASDAQ: PEAR) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PEAR stands at 4.1M. In comparison, CMAX has a market cap of 1.6M. Regarding current trading prices, PEAR is priced at $0.03 on the NASDAQ, while CMAX trades at $0.42.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PEAR currently has a P/E ratio of -0.08, whereas CMAX's P/E ratio is -0.00. In terms of profitability, PEAR's ROE is -0.39%, compared to CMAX's ROE of -2.01%. Regarding short-term risk, PEAR is more volatile compared to CMAX. This indicates higher risk in terms of short-term price fluctuations for PEAR.Check CMAX's competition here
Healthcare Triangle, Inc. (NASDAQ: HCTI)
PEAR vs HCTI Comparison August 2026
Pear Therapeutics, Inc. (NASDAQ: PEAR) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PEAR stands at 4.1M. In comparison, HCTI has a market cap of 1.4M. Regarding current trading prices, PEAR is priced at $0.03 on the NASDAQ, while HCTI trades at $1.25.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PEAR currently has a P/E ratio of -0.08, whereas HCTI's P/E ratio is -0.16. In terms of profitability, PEAR's ROE is -0.39%, compared to HCTI's ROE of -0.68%. Regarding short-term risk, PEAR is more volatile compared to HCTI. This indicates higher risk in terms of short-term price fluctuations for PEAR.Check HCTI's competition here
VSee Health, Inc. (NASDAQ: VSEEW)
PEAR vs VSEEW Comparison August 2026
Pear Therapeutics, Inc. (NASDAQ: PEAR) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PEAR stands at 4.1M. In comparison, VSEEW has a market cap of 1.4M. Regarding current trading prices, PEAR is priced at $0.03 on the NASDAQ, while VSEEW trades at $0.02.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PEAR currently has a P/E ratio of -0.08, whereas VSEEW's P/E ratio is -0.04. In terms of profitability, PEAR's ROE is -0.39%, compared to VSEEW's ROE of -115.71%. Regarding short-term risk, PEAR is less volatile compared to VSEEW. This indicates lower risk in terms of short-term price fluctuations for PEAR.Check VSEEW's competition here
MSP Recovery, Inc. (NASDAQ: LIFWZ)
PEAR vs LIFWZ Comparison August 2026
Pear Therapeutics, Inc. (NASDAQ: PEAR) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PEAR stands at 4.1M. In comparison, LIFWZ has a market cap of 1.3M. Regarding current trading prices, PEAR is priced at $0.03 on the NASDAQ, while LIFWZ trades at $0.07.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PEAR currently has a P/E ratio of -0.08, whereas LIFWZ's P/E ratio is N/A. In terms of profitability, PEAR's ROE is -0.39%, compared to LIFWZ's ROE of +1.56%. Regarding short-term risk, PEAR is more volatile compared to LIFWZ. This indicates higher risk in terms of short-term price fluctuations for PEAR.Check LIFWZ's competition here
Aclarion, Inc. (NASDAQ: ACON)
PEAR vs ACON Comparison August 2026
Pear Therapeutics, Inc. (NASDAQ: PEAR) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PEAR stands at 4.1M. In comparison, ACON has a market cap of 1.2M. Regarding current trading prices, PEAR is priced at $0.03 on the NASDAQ, while ACON trades at $2.29.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PEAR currently has a P/E ratio of -0.08, whereas ACON's P/E ratio is -0.25. In terms of profitability, PEAR's ROE is -0.39%, compared to ACON's ROE of -0.59%. Regarding short-term risk, PEAR is more volatile compared to ACON. This indicates higher risk in terms of short-term price fluctuations for PEAR.Check ACON's competition here
EUDA Health Holdings Limited (NASDAQ: EUDAW)
PEAR vs EUDAW Comparison August 2026
Pear Therapeutics, Inc. (NASDAQ: PEAR) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PEAR stands at 4.1M. In comparison, EUDAW has a market cap of 952.7K. Regarding current trading prices, PEAR is priced at $0.03 on the NASDAQ, while EUDAW trades at $0.03.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PEAR currently has a P/E ratio of -0.08, whereas EUDAW's P/E ratio is 0.03. In terms of profitability, PEAR's ROE is -0.39%, compared to EUDAW's ROE of +1.20%. Regarding short-term risk, PEAR is more volatile compared to EUDAW. This indicates higher risk in terms of short-term price fluctuations for PEAR.Check EUDAW's competition here
VSee Health, Inc. (NASDAQ: VSEE)
PEAR vs VSEE Comparison August 2026
Pear Therapeutics, Inc. (NASDAQ: PEAR) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PEAR stands at 4.1M. In comparison, VSEE has a market cap of 816.5K. Regarding current trading prices, PEAR is priced at $0.03 on the NASDAQ, while VSEE trades at $0.05.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PEAR currently has a P/E ratio of -0.08, whereas VSEE's P/E ratio is -0.10. In terms of profitability, PEAR's ROE is -0.39%, compared to VSEE's ROE of -115.71%. Regarding short-term risk, PEAR is more volatile compared to VSEE. This indicates higher risk in terms of short-term price fluctuations for PEAR.Check VSEE's competition here
MSP Recovery, Inc. (NASDAQ: MSPRZ)
PEAR vs MSPRZ Comparison August 2026
Pear Therapeutics, Inc. (NASDAQ: PEAR) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PEAR stands at 4.1M. In comparison, MSPRZ has a market cap of 550.4K. Regarding current trading prices, PEAR is priced at $0.03 on the NASDAQ, while MSPRZ trades at $0.04.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PEAR currently has a P/E ratio of -0.08, whereas MSPRZ's P/E ratio is N/A. In terms of profitability, PEAR's ROE is -0.39%, compared to MSPRZ's ROE of +1.56%. Regarding short-term risk, PEAR is less volatile compared to MSPRZ. This indicates lower risk in terms of short-term price fluctuations for PEAR.Check MSPRZ's competition here
Akerna Corp. (NASDAQ: KERN)
PEAR vs KERN Comparison August 2026
Pear Therapeutics, Inc. (NASDAQ: PEAR) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PEAR stands at 4.1M. In comparison, KERN has a market cap of 162.3K. Regarding current trading prices, PEAR is priced at $0.03 on the NASDAQ, while KERN trades at $0.31.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PEAR currently has a P/E ratio of -0.08, whereas KERN's P/E ratio is -0.01. In terms of profitability, PEAR's ROE is -0.39%, compared to KERN's ROE of -0.20%. Regarding short-term risk, PEAR is more volatile compared to KERN. This indicates higher risk in terms of short-term price fluctuations for PEAR.Check KERN's competition here
Akerna Corp. (NASDAQ: KERNW)
PEAR vs KERNW Comparison August 2026
Pear Therapeutics, Inc. (NASDAQ: PEAR) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PEAR stands at 4.1M. In comparison, KERNW has a market cap of 162.3K. Regarding current trading prices, PEAR is priced at $0.03 on the NASDAQ, while KERNW trades at $0.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PEAR currently has a P/E ratio of -0.08, whereas KERNW's P/E ratio is -0.00. In terms of profitability, PEAR's ROE is -0.39%, compared to KERNW's ROE of -0.20%. Regarding short-term risk, PEAR is less volatile compared to KERNW. This indicates lower risk in terms of short-term price fluctuations for PEAR.Check KERNW's competition here
MSP Recovery, Inc. (NASDAQ: LIFWW)
PEAR vs LIFWW Comparison August 2026
Pear Therapeutics, Inc. (NASDAQ: PEAR) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PEAR stands at 4.1M. In comparison, LIFWW has a market cap of 60.1K. Regarding current trading prices, PEAR is priced at $0.03 on the NASDAQ, while LIFWW trades at $0.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PEAR currently has a P/E ratio of -0.08, whereas LIFWW's P/E ratio is N/A. In terms of profitability, PEAR's ROE is -0.39%, compared to LIFWW's ROE of +1.56%. Regarding short-term risk, PEAR is more volatile compared to LIFWW. This indicates higher risk in terms of short-term price fluctuations for PEAR.Check LIFWW's competition here
Zhongchao Inc. (NASDAQ: ZCMD)
PEAR vs ZCMD Comparison August 2026
Pear Therapeutics, Inc. (NASDAQ: PEAR) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PEAR stands at 4.1M. In comparison, ZCMD has a market cap of 37.5K. Regarding current trading prices, PEAR is priced at $0.03 on the NASDAQ, while ZCMD trades at $1.08.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PEAR currently has a P/E ratio of -0.08, whereas ZCMD's P/E ratio is -0.04. In terms of profitability, PEAR's ROE is -0.39%, compared to ZCMD's ROE of -0.32%. Regarding short-term risk, PEAR is more volatile compared to ZCMD. This indicates higher risk in terms of short-term price fluctuations for PEAR.Check ZCMD's competition here
CareMax, Inc. (NASDAQ: CMAXW)
PEAR vs CMAXW Comparison August 2026
Pear Therapeutics, Inc. (NASDAQ: PEAR) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PEAR stands at 4.1M. In comparison, CMAXW has a market cap of 36.4K. Regarding current trading prices, PEAR is priced at $0.03 on the NASDAQ, while CMAXW trades at $0.01.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PEAR currently has a P/E ratio of -0.08, whereas CMAXW's P/E ratio is N/A. In terms of profitability, PEAR's ROE is -0.39%, compared to CMAXW's ROE of -2.01%. Regarding short-term risk, PEAR is more volatile compared to CMAXW. This indicates higher risk in terms of short-term price fluctuations for PEAR.Check CMAXW's competition here
Aclarion, Inc. (NASDAQ: ACONW)
PEAR vs ACONW Comparison August 2026
Pear Therapeutics, Inc. (NASDAQ: PEAR) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PEAR stands at 4.1M. In comparison, ACONW has a market cap of 13.2K. Regarding current trading prices, PEAR is priced at $0.03 on the NASDAQ, while ACONW trades at $0.02.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PEAR currently has a P/E ratio of -0.08, whereas ACONW's P/E ratio is N/A. In terms of profitability, PEAR's ROE is -0.39%, compared to ACONW's ROE of -0.59%. Regarding short-term risk, PEAR is more volatile compared to ACONW. This indicates higher risk in terms of short-term price fluctuations for PEAR.Check ACONW's competition here
Cerner Corporation (NASDAQ: CERN)
PEAR vs CERN Comparison August 2026
Pear Therapeutics, Inc. (NASDAQ: PEAR) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PEAR stands at 4.1M. In comparison, CERN has a market cap of 0. Regarding current trading prices, PEAR is priced at $0.03 on the NASDAQ, while CERN trades at $94.92.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PEAR currently has a P/E ratio of -0.08, whereas CERN's P/E ratio is 55.84. In terms of profitability, PEAR's ROE is -0.39%, compared to CERN's ROE of +0.14%. Regarding short-term risk, PEAR is more volatile compared to CERN. This indicates higher risk in terms of short-term price fluctuations for PEAR.Check CERN's competition here
Alkuri Global Acquisition Corp. (NASDAQ: KURIU)
PEAR vs KURIU Comparison August 2026
Pear Therapeutics, Inc. (NASDAQ: PEAR) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PEAR stands at 4.1M. In comparison, KURIU has a market cap of 0. Regarding current trading prices, PEAR is priced at $0.03 on the NASDAQ, while KURIU trades at $9.50.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PEAR currently has a P/E ratio of -0.08, whereas KURIU's P/E ratio is N/A. In terms of profitability, PEAR's ROE is -0.39%, compared to KURIU's ROE of +1.06%. Regarding short-term risk, PEAR is more volatile compared to KURIU. This indicates higher risk in terms of short-term price fluctuations for PEAR.Check KURIU's competition here
Convey Health Solutions Holdings, Inc. (NYSE: CNVY)
PEAR vs CNVY Comparison August 2026
Pear Therapeutics, Inc. (NASDAQ: PEAR) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PEAR stands at 4.1M. In comparison, CNVY has a market cap of 0. Regarding current trading prices, PEAR is priced at $0.03 on the NASDAQ, while CNVY trades at $10.51.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PEAR currently has a P/E ratio of -0.08, whereas CNVY's P/E ratio is -71.50. In terms of profitability, PEAR's ROE is -0.39%, compared to CNVY's ROE of -0.02%. Regarding short-term risk, PEAR is more volatile compared to CNVY. This indicates higher risk in terms of short-term price fluctuations for PEAR.Check CNVY's competition here
Change Healthcare Inc. (NASDAQ: CHNGU)
PEAR vs CHNGU Comparison August 2026
Pear Therapeutics, Inc. (NASDAQ: PEAR) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PEAR stands at 4.1M. In comparison, CHNGU has a market cap of 0. Regarding current trading prices, PEAR is priced at $0.03 on the NASDAQ, while CHNGU trades at $73.71.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PEAR currently has a P/E ratio of -0.08, whereas CHNGU's P/E ratio is N/A. In terms of profitability, PEAR's ROE is -0.39%, compared to CHNGU's ROE of -0.05%. Regarding short-term risk, PEAR is more volatile compared to CHNGU. This indicates higher risk in terms of short-term price fluctuations for PEAR.Check CHNGU's competition here
NantHealth, Inc. (NASDAQ: NH)
PEAR vs NH Comparison August 2026
Pear Therapeutics, Inc. (NASDAQ: PEAR) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PEAR stands at 4.1M. In comparison, NH has a market cap of 0. Regarding current trading prices, PEAR is priced at $0.03 on the NASDAQ, while NH trades at $1.35.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PEAR currently has a P/E ratio of -0.08, whereas NH's P/E ratio is -0.12. In terms of profitability, PEAR's ROE is -0.39%, compared to NH's ROE of +0.35%. Regarding short-term risk, PEAR is less volatile compared to NH. This indicates lower risk in terms of short-term price fluctuations for PEAR.Check NH's competition here
Sema4 Holdings Corp. (NASDAQ: SMFRW)
PEAR vs SMFRW Comparison August 2026
Pear Therapeutics, Inc. (NASDAQ: PEAR) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PEAR stands at 4.1M. In comparison, SMFRW has a market cap of 0. Regarding current trading prices, PEAR is priced at $0.03 on the NASDAQ, while SMFRW trades at $0.02.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PEAR currently has a P/E ratio of -0.08, whereas SMFRW's P/E ratio is N/A. In terms of profitability, PEAR's ROE is -0.39%, compared to SMFRW's ROE of -0.39%. Regarding short-term risk, PEAR is more volatile compared to SMFRW. This indicates higher risk in terms of short-term price fluctuations for PEAR.Check SMFRW's competition here
CareCloud, Inc. (NASDAQ: MTBC)
PEAR vs MTBC Comparison August 2026
Pear Therapeutics, Inc. (NASDAQ: PEAR) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PEAR stands at 4.1M. In comparison, MTBC has a market cap of 0. Regarding current trading prices, PEAR is priced at $0.03 on the NASDAQ, while MTBC trades at $3.13.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PEAR currently has a P/E ratio of -0.08, whereas MTBC's P/E ratio is N/A. In terms of profitability, PEAR's ROE is -0.39%, compared to MTBC's ROE of +0.19%. Regarding short-term risk, PEAR is more volatile compared to MTBC. This indicates higher risk in terms of short-term price fluctuations for PEAR.Check MTBC's competition here
MSP Recovery, Inc. (NASDAQ: MSPRV)
PEAR vs MSPRV Comparison August 2026
Pear Therapeutics, Inc. (NASDAQ: PEAR) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PEAR stands at 4.1M. In comparison, MSPRV has a market cap of 0. Regarding current trading prices, PEAR is priced at $0.03 on the NASDAQ, while MSPRV trades at $0.07.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PEAR currently has a P/E ratio of -0.08, whereas MSPRV's P/E ratio is N/A. In terms of profitability, PEAR's ROE is -0.39%, compared to MSPRV's ROE of N/A. Regarding short-term risk, PEAR is more volatile compared to MSPRV. This indicates higher risk in terms of short-term price fluctuations for PEAR.Check MSPRV's competition here
Nava Health MD, LLC (NASDAQ: NAVA)
PEAR vs NAVA Comparison August 2026
Pear Therapeutics, Inc. (NASDAQ: PEAR) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PEAR stands at 4.1M. In comparison, NAVA has a market cap of 0. Regarding current trading prices, PEAR is priced at $0.03 on the NASDAQ, while NAVA trades at $0.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PEAR currently has a P/E ratio of -0.08, whereas NAVA's P/E ratio is N/A. In terms of profitability, PEAR's ROE is -0.39%, compared to NAVA's ROE of +0.15%. Regarding short-term risk, PEAR is not fully comparable compared to NAVA. This indicates unavailable risk data in terms of short-term price fluctuations for PEAR.Check NAVA's competition here
Change Healthcare Inc. (NASDAQ: CHNG)
PEAR vs CHNG Comparison August 2026
Pear Therapeutics, Inc. (NASDAQ: PEAR) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PEAR stands at 4.1M. In comparison, CHNG has a market cap of 0. Regarding current trading prices, PEAR is priced at $0.03 on the NASDAQ, while CHNG trades at $27.49.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PEAR currently has a P/E ratio of -0.08, whereas CHNG's P/E ratio is -152.72. In terms of profitability, PEAR's ROE is -0.39%, compared to CHNG's ROE of -0.05%. Regarding short-term risk, PEAR is more volatile compared to CHNG. This indicates higher risk in terms of short-term price fluctuations for PEAR.Check CHNG's competition here
IMS Health Holdings, Inc. (NYSE: IMS)
PEAR vs IMS Comparison August 2026
Pear Therapeutics, Inc. (NASDAQ: PEAR) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PEAR stands at 4.1M. In comparison, IMS has a market cap of 0. Regarding current trading prices, PEAR is priced at $0.03 on the NASDAQ, while IMS trades at $31.34.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PEAR currently has a P/E ratio of -0.08, whereas IMS's P/E ratio is N/A. In terms of profitability, PEAR's ROE is -0.39%, compared to IMS's ROE of +0.27%. Regarding short-term risk, PEAR is more volatile compared to IMS. This indicates higher risk in terms of short-term price fluctuations for PEAR.Check IMS's competition here
CareCloud, Inc. (NASDAQ: MTBCP)
PEAR vs MTBCP Comparison August 2026
Pear Therapeutics, Inc. (NASDAQ: PEAR) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PEAR stands at 4.1M. In comparison, MTBCP has a market cap of 0. Regarding current trading prices, PEAR is priced at $0.03 on the NASDAQ, while MTBCP trades at $26.91.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PEAR currently has a P/E ratio of -0.08, whereas MTBCP's P/E ratio is N/A. In terms of profitability, PEAR's ROE is -0.39%, compared to MTBCP's ROE of +0.17%. Regarding short-term risk, PEAR is more volatile compared to MTBCP. This indicates higher risk in terms of short-term price fluctuations for PEAR.Check MTBCP's competition here
Castlight Health, Inc. (NYSE: CSLT)
PEAR vs CSLT Comparison August 2026
Pear Therapeutics, Inc. (NASDAQ: PEAR) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PEAR stands at 4.1M. In comparison, CSLT has a market cap of 0. Regarding current trading prices, PEAR is priced at $0.03 on the NASDAQ, while CSLT trades at $2.05.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PEAR currently has a P/E ratio of -0.08, whereas CSLT's P/E ratio is -37.27. In terms of profitability, PEAR's ROE is -0.39%, compared to CSLT's ROE of -0.42%. Regarding short-term risk, PEAR is more volatile compared to CSLT. This indicates higher risk in terms of short-term price fluctuations for PEAR.Check CSLT's competition here
Affymetrix, Inc. (NASDAQ: AFFX)
PEAR vs AFFX Comparison August 2026
Pear Therapeutics, Inc. (NASDAQ: PEAR) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PEAR stands at 4.1M. In comparison, AFFX has a market cap of 0. Regarding current trading prices, PEAR is priced at $0.03 on the NASDAQ, while AFFX trades at $14.01.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PEAR currently has a P/E ratio of -0.08, whereas AFFX's P/E ratio is N/A. In terms of profitability, PEAR's ROE is -0.39%, compared to AFFX's ROE of +0.03%. Regarding short-term risk, PEAR is more volatile compared to AFFX. This indicates higher risk in terms of short-term price fluctuations for PEAR.Check AFFX's competition here
CareCloud, Inc. (NASDAQ: MTBCO)
PEAR vs MTBCO Comparison August 2026
Pear Therapeutics, Inc. (NASDAQ: PEAR) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PEAR stands at 4.1M. In comparison, MTBCO has a market cap of 0. Regarding current trading prices, PEAR is priced at $0.03 on the NASDAQ, while MTBCO trades at $25.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PEAR currently has a P/E ratio of -0.08, whereas MTBCO's P/E ratio is N/A. In terms of profitability, PEAR's ROE is -0.39%, compared to MTBCO's ROE of +0.17%. Regarding short-term risk, PEAR is more volatile compared to MTBCO. This indicates higher risk in terms of short-term price fluctuations for PEAR.Check MTBCO's competition here